CoChat

Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease

Kent, David M., Jafar, Tazeen H., Hayward, Rodney A., Tighiouart, Hocine, Landa, Marcia, de Jong, Paul, de Zeeuw, Dick, Remuzzi, Giuseppe, Kamper, Anne-Lise, Levey, Andrew S. · 2007 · Journal of the American Society of Nephrology

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

It is unclear whether patients with nondiabetic kidney disease benefit from angiotensin-converting enzyme inhibitor (ACEI) therapy when they are at low risk for disease progression or when they have low urinary protein excretion. With the use of a combined database from 11 randomized, clinical trials (n = 1860), a Cox proportional hazards model, based on known predictors of risk and the composite outcome kidney failure or creatinine doubling, was developed and used to stratify patients into equal-sized quartiles of risk. Outcome risk and treatment effect were examined across various risk strata. Use of this risk model for targeting ACEI therapy was also compared with a strategy based on urinary protein excretion alone. Control patients in the highest quartile of predicted risk had an annualized outcome rate of 28.7%, whereas control patients in the lowest quartile of predicted risk had an annualized outcome rate of 0.4%. Despite the extreme variation in risk, there was no variation in the degree of benefit of ACEI therapy (P = 0.93 for the treatment x risk interaction). Significant interaction was detected between baseline urine protein and ACEI therapy (P = 0.003). When patients were stratified according to their baseline urinary protein excretion, among the subgroup of patients with proteinuria > or =500 mg/d, significant treatment effect was seen across all patients with a measurable outcome risk, including those at relatively low risk (1.7% annualized risk for progression). However, there was no benefit of ACEI therapy among patients with proteinuria <500 mg/d, even among higher risk patients (control outcome rate 19.7%). Patients with nondiabetic kidney disease vary considerably in their risk for disease progression, but the treatment effect of ACEI does not vary across risk strata. Patients with proteinuria <500 mg/d do not seem to benefit, even when at relatively high risk for progression.

Overview

Integrity signals

Registry

Crossref · 10.1681/asn.2006101081

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 39 references

Cited by

See all 162

Metadata

Authors
Kent, D. M., Jafar, T. H., Hayward, R. A., Tighiouart, H., Landa, M., de Jong, P., de Zeeuw, D., Remuzzi, G., Kamper, A.-L., & Levey, A. S.
Affiliations
  • Tufts University (US)
  • Aga Khan University (PK)
  • Michigan Medicine (US)
  • Mario Negri Institute for Pharmacological Research (IT)
  • University of Copenhagen (DK)
Corresponding author
  • Kent, David M.
  • Tighiouart, Hocine
  • Landa, Marcia
  • Levey, Andrew S.
Venue
Journal of the American Society of Nephrology
Published
2007-06
Volume
18
Issue
6
Pages
1959-1965
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2155101891
Cited by
162
References
39
Citations by year
2026: 3 · 2025: 3 · 2024: 5 · 2023: 6 · 2022: 3 · 2021: 3 · 2020: 6 · 2019: 14 · 2018: 7 · 2017: 5 · 2016: 11 · 2015: 9 · 2014: 12 · 2013: 8 · 2012: 8
FWCI
10.94
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of the American Society of Nephrology (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
non-diabetic kidney disease, ACE inhibitors, disease progression, urinary protein excretion, proteinuria, risk stratification, renal failure, treatment effect heterogeneity
MeSH terms
Aged, Algorithms, Angiotensin-Converting Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Proteinuria, Risk Factors, Models, Statistical, Randomized Controlled Trials as Topic, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease. https://app.cochat.ai/papers/10.1681/asn.2006101081
The paper
Kent, D. M., Jafar, T. H., Hayward, R. A., Tighiouart, H., Landa, M., de Jong, P., de Zeeuw, D., Remuzzi, G., Kamper, A.-L., & Levey, A. S. (2007). Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2006101081

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.